topic

786 Distinct efficacy and immunological responses to aPD-1, aPD-L1 and aPD-L2 immunotherapy in B16 melanoma in aged versus young hosts includes T-cell stem cell effects and PD-L2 expression differences
Myrna Garcia, Alvaro Padron, Yilun Deng, Aravind Kancharla, Ryan Reyes, Harshita Gupta, Tyler Curiel

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A470-A471; DOI: 10.1136/jitc-2020-SITC2020.0786
788 Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety and cerebrospinal fluid biomarkers
Jarushka Naidoo, Karisa Schreck, Wei Fu, Chen Hu, Roisin Connolly, Cesar Santa-Maria, Evan Lipson, Matthias Holdhoff, Patrick Forde, Joanne Riemer, Amanda Barnes, Nafi Aygun, Lawrence Kleinberg, Kristin Redmond, Christopher Douville, Chetan Bettegowda, Arun Venkatesan, Stuart Grossman, Julie Brahmer

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A471-A472; DOI: 10.1136/jitc-2020-SITC2020.0788
790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)
Matthew Krebs, Margarita Majem, Enriqueta Felip, Martin Forster, Bernard Doger, Tim Clay, Enric Carcereny, Julio Peguero, Leora Horn, Pawan Bajaj, Patricia Roxburgh, Chrystelle Brignone, Christian Mueller, Frederic Triebel

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A472-A473; DOI: 10.1136/jitc-2020-SITC2020.0790
791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)
Yuqin Song, Keshu Zhou, Chuan Jin, Zhengzi Qian, Ming Hou, Lei Fan, Fei Li, Kaiyang Ding, Hui Zhou, Xiaoling Li, Bing Chen, Xiuhua Sun, Xianmin Song, Ming Jiang, Qingyuan Zhang, Lihong Liu, Guohua Yu, Yu Hu, Zheng Zhao, Ligen Liu, Hongwei Xue, Jun Luo, Bai He, Xiaoping Jin, Maxwell Wang, Baiyong Li, Yu Xia, Jun Zhu

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A473-A474; DOI: 10.1136/jitc-2020-SITC2020.0791
794 Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors
Victor Moreno, Caroline Gaudy-Marqueste, Martin Wermke, Antoine Italiano, Emanuela Romano, Aurelien Marabelle, Emilee Connors, Heng Zhou, Konstantin Dobrenkov, Elliot Chartash, Emiliano Calvo, Emiliano Calvo Aller

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A474-A475; DOI: 10.1136/jitc-2020-SITC2020.0794
796 A phase I/II trial combining avelumab and trabectedin for advanced liposarcoma and leiomyosarcoma
Michael Wagner, Qianchuan He, Yuzheng Zhang, Lee Cranmer, Elizabeth Loggers, Sabrina McDonnell, Shannon Maxwell, Seth Pollack

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A476; DOI: 10.1136/jitc-2020-SITC2020.0796
799 Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data
Pablo Fernandez-Penas, Matteo Carlino, Katy Tsai, Victoria Atkinson, Monaster Shaheen, Sajeve Thomas, Catalin Mihalcioiu, Tom Van Hagen, Rachel Roberts-Thomson, Andrew Haydon, Andrew Mant, Marcus Butler, Gregory Daniels, Elizabeth Buchbinder, John Hyngstrom, Mecker Moller, Igor Puzanov, C Lance Cowey, Eric Whitman, Carmen Ballesteros-Merino, Shawn Jensen, Bernard Fox, Emmett Schmidt, Clemens Krepler, Scott Diede, Erica Browning, Reneta Hermiz, Lauren Svenson, Jon Salazar, Jack Lee, Christopher Baker, Donna Bannavong, Jendy Sell, Kellie Malloy Foerter, David Canton, Sandra Aung, Christopher Twitty, Alain Algazi, Adil Daud

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A477-A478; DOI: 10.1136/jitc-2020-SITC2020.0799
801 PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients
Erika Hamilton, Sarah Nikiforow, Philip Bardwell, Christine McInnis, Jeffrey Zhang, George Blumenschein, Mihaela Cristea, Keren Osman, Anthony Shields, Marlyane Motta, Sanela Bilic, Oliver Schoenborn-Kellenberger, James Rakestraw, Shawn Carey, Elena Geretti, Karsten Sauer, Tim Harris, Tap Maniar, Becker Hewes, Thomas Andresen, Jonathan Fitzgerald, Harriet Kluger

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A479-A480; DOI: 10.1136/jitc-2020-SITC2020.0801
78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma
Dingwei Ye, Aiping Zhou, Qing Zou, Hanzhong Li, Cheng Fu, Hailong Hu, Jian Huang, Wei Shen, Yun Zhang, Xiaopeng Ma, Pei Zhang, Ruiqi Huang, Xiusong Qiu, Lilin Zhang, Feng Bi

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A48-A49; DOI: 10.1136/jitc-2020-SITC2020.0078
803 Phase 1/2 study using ENB-003, a first-in-class selective ETBRi, in combination with pembrolizumab in subjects with advanced refractory solid tumors
Sumayah Jamal, Adnan Nagrial, Anthony Joshua, Richard Eek, Sumayah Jamal

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A480-A481; DOI: 10.1136/jitc-2020-SITC2020.0803

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages